Voyager Therapeutics EBITDA 2014-2022 | VYGR

Voyager Therapeutics ebitda from 2014 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Voyager Therapeutics Annual EBITDA
(Millions of US $)
2021 $-68
2020 $31
2019 $-52
2018 $-91
2017 $-70
2016 $-40
2015 $-19
2014 $-14
2013 $-4
Voyager Therapeutics Quarterly EBITDA
(Millions of US $)
2022-03-31 $-19
2021-12-31 $7
2021-09-30 $-24
2021-06-30 $-27
2021-03-31 $-24
2020-12-31 $-23
2020-09-30 $86
2020-06-30 $-8
2020-03-31 $-24
2019-12-31 $-14
2019-09-30 $-18
2019-06-30 $9
2019-03-31 $-29
2018-12-31 $-23
2018-09-30 $-21
2018-06-30 $-26
2018-03-31 $-21
2017-12-31 $-12
2017-09-30 $-23
2017-06-30 $-18
2017-03-31 $-17
2016-12-31 $-14
2016-09-30 $-10
2016-06-30 $-9
2016-03-31 $-7
2015-12-31 $-7
2015-09-30 $-4
2015-06-30 $-4
2015-03-31 $-5
2014-12-31 $0
2014-09-30 $-4
2014-06-30
2014-03-31
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.227B $0.037B
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.938B 9.97
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.718B 16.92
Biohaven Pharmaceutical Holding (BHVN) United States $10.276B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.817B 46.07
Emergent Biosolutions (EBS) United States $1.560B 6.68
Myovant Sciences (MYOV) United Kingdom $1.185B 0.00
Zymeworks (ZYME) Canada $0.306B 0.00
Gelesis Holdings (GLS) United States $0.112B 0.00
Ambrx Biopharma (AMAM) United States $0.102B 0.00
Enzo Biochem (ENZ) United States $0.101B 0.00
SQZ Biotechnologies (SQZ) United States $0.090B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00